Biotech's Hottest New Strategy: Raiding Big Pharma's Junk Drawer

The syndicate runs deep. Regeneron Ventures participated, along with Balyasny Asset Management, Luma Group, Samsara BioCapital, Longwood Fund, and Finchley Healthcare Ventures. Perhaps most interesting: Galapagos itself invested in the round, essentially betting that its own discarded assets still have value when someone else is driving.

The round was oversubscribed, meaning more investors wanted in than there was room for. In a biotech funding environment that's been notoriously picky since the 2022 downturn, that's a strong signal.

The Drug That Got a Second Life

Coultreon's lead candidate is COL-5671, an oral inhibitor of something called salt-inducible kinase 3 (SIK3). In plain English, SIK3 is a protein that plays a role in how your immune system ramps up inflammation. Block it, and you might be able to calm down the overactive immune responses that drive diseases like psoriasis and ulcerative colitis.

The drug is already in phase 1 trials, meaning early safety testing in humans is underway. The $125 million will push it into phase 2 studies (where you start testing whether it actually works) in both psoriasis and ulcerative colitis, with proof-of-concept data targeted for 2027.

The autoimmune market is enormous and fiercely competitive, but there's still room for oral drugs that work through novel mechanisms. If COL-5671 delivers clean data in two indications simultaneously, Coultreon could become an acquisition target almost overnight. Preclinical work also hints at potential in Crohn's disease and rheumatoid arthritis, which would widen the opportunity considerably.

Beyond autoimmune, Coultreon's pipeline includes candidates for bladder cancer, lung cancer, and solid tumors. It's not a one-trick pony.

Why This Playbook Is Everywhere Now

Coultreon isn't an isolated case. It's part of a growing trend that's reshaping how biotech innovation gets funded.

The math is brutal for big pharma right now. The industry faces roughly $300 billion in revenue losses from patent expirations by 2028. That's forcing companies to make hard choices about which programs to keep and which to cut.

All those divestitures create opportunity for nimble startups. Biopharma M&A value surged 79% through late 2025, with much of that activity driven by buyers scooping up exactly these kinds of orphaned programs.

It's like the housing market after a foreclosure wave: the houses are still perfectly good. They just need a new owner with the resources and patience to fix them up.

The Risks Nobody Wants to Talk About

This strategy sounds elegant, but it's not risk-free. There's usually a reason big companies deprioritize drugs, and "we just got distracted" isn't always the honest answer. Sometimes the early data was underwhelming. Sometimes the competitive landscape shifted. Sometimes manufacturing turned out to be a nightmare.

Coultreon has a few things working in its favor, though. COL-5671 is already in human testing, which removes the biggest binary risk (whether the drug is safe enough to give to people). The investor syndicate includes Regeneron Ventures, which brings deep immunology expertise, not just money. And having Galapagos as an investor means the original developer is still bought in.

The 2027 timeline for proof-of-concept data is aggressive but realistic for a drug already in phase 1. If the data looks good, Coultreon will have options: raise more money, partner with a larger company, or become an acquisition target itself.

The Bigger Picture

Galapagos, for its part, is going through its own identity crisis. The company is planning to rebrand as Lakefront Biotherapeutics as it pivots yet again, this time toward developing an autoimmune T-cell engager connected to Gilead's $1.675 billion acquisition of Ouro Medicines. It's a company that has reinvented itself so many times, its original thesis is barely recognizable.

Coultreon represents the other side of that story: what happens to the good science that gets left behind when corporate strategy zigs and zags. In a world where big pharma increasingly acts like a portfolio manager rather than a drug developer, the real innovation might come from smaller companies willing to do the unglamorous work of picking up what others dropped.

For $125 million, Coultreon is betting it found diamonds in the discount bin. By 2027, we'll know if they were right.